drugset / Trial / NCT02908074
A 6 Month Safety Extension Study of MBGS205
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)
Timeline
- Start
- 2016-11-15
- Primary completion
- 2018-09-08
- Completion
- 2018-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGS649 | Unknown | 0.1 mg | Oral |
| Subject | BGS649 | Unknown | 0.3 mg | Oral |
| Subject | BGS649 | Unknown | 1 mg | Oral |